Published in Blood Weekly, July 13th, 2006
"We compared the safety and efficacy of allogeneic stem cell transplantation (allo-SCT) after reduced-intensity conditioning using either unrelated umbilical cord blood (UCB) donors or matched-sibling donors (MSDs) for 21 adults at high risk with advanced Hodgkin lymphoma (UCB, n=9; MSD, n=12).
"Both groups were comparable except for younger age in the UCB cohort (median, 28 vs. 42 years; p=0.02)," wrote investigators in the United States.
According to N.S. Majhail and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.